Cannabinoids Guide: THC, CBD, CBG & More
THC may get most of the attention, but cannabis contains a much larger family of compounds called cannabinoids. If you are searching for to have the cannabinoids explained, look no further.
CBD, CBG, CBN, CBC, and THCV can all appear alongside THC, sometimes in meaningful amounts and sometimes only as minor parts of a product's cannabinoid profile. They are chemically related, but that does not mean they behave the same way in the body.
Some cannabinoids are intoxicating. Others are not considered intoxicating at typical amounts. Some interact directly with the cannabinoid receptors that form part of the body's endocannabinoid system, while others appear to influence a wider collection of biological targets.
And although cannabis labels increasingly advertise specific cannabinoids and ratios, the science is not equally developed for all of them. THC and CBD have received considerably more human research than minor cannabinoids such as CBG, CBN, CBC, and THCV. Research into these less abundant cannabinoids is growing, but many popular claims about their effects are still based primarily on laboratory, animal, or early human studies.
This cannabinoid guide breaks down the major compounds you are likely to encounter on a cannabis label, how they differ, what cannabinoid ratios mean, and how to look beyond THC percentage when comparing products.
Compare Common Cannabinoids
Cannabinoids share a botanical origin, but they should not be treated as interchangeable.
THC is the primary intoxicating cannabinoid in cannabis and is responsible for much of the traditional cannabis high.
CBD does not produce the traditional THC-like high and is one of the most extensively researched non-intoxicating cannabinoids.
CBG is generally considered non-intoxicating and is a minor cannabinoid connected to an important cannabinoid precursor called CBGA.
CBN is commonly associated with aged cannabis because THC can gradually degrade into CBN. It appears frequently in products marketed for nighttime use, although research into its effects is still developing.
CBC is another generally non-intoxicating minor cannabinoid. It receives much less attention than THC or CBD, and human research remains limited.
THCV is structurally related to THC but has distinct pharmacology. Its effects can vary depending on dose and other factors, which makes simple comparisons with THC difficult.
These descriptions are useful starting points, not predictions of exactly how a particular product will make someone feel.
Cannabinoid dose, product format, tolerance, individual biology, other cannabinoids, and the rest of the plant's chemistry can all affect the experience.
What Are Cannabinoids?
Cannabinoids are chemical compounds that interact with biological systems in the body, including the endocannabinoid system.
The cannabis plant produces naturally occurring cannabinoids called phytocannabinoids. Researchers have identified well over 100 of these compounds, although most occur at much lower concentrations than THC or CBD.
Your body also produces its own cannabinoids, known as endocannabinoids. Two of the best-known are anandamide and 2-AG.
The endocannabinoid system includes cannabinoid receptors, enzymes, and signaling molecules involved in a variety of physiological processes.
Two of its best-known receptors are:
CB1 receptors, which are especially abundant throughout the central nervous system.
CB2 receptors, which are found throughout the body and are particularly associated with immune tissues and signaling.
THC interacts directly with CB1 and CB2 receptors, including the CB1 activity responsible for much of its intoxicating effect. Other cannabinoids can behave very differently. CBD, CBG, CBC, CBN, and THCV each have their own pharmacology and may interact with targets outside the traditional CB1 and CB2 system as well.
Cannabinoids also usually begin life in cannabis in their acidic forms.
For example:
THCA → THC
CBDA → CBD
CBGA → CBG
CBCA → CBC
THCVA → THCV
Heat can remove part of the acidic cannabinoid molecule through a process called decarboxylation, converting compounds such as THCA into THC.
That is why raw cannabis flower generally contains much more THCA than active delta-9 THC before it is smoked, vaped, or heated.
THC
Delta-9-tetrahydrocannabinol, usually shortened to THC, is the primary cannabinoid associated with the intoxicating effects of cannabis.
THC acts as a partial agonist at CB1 and CB2 cannabinoid receptors. Its activity at CB1 receptors in the central nervous system plays a major role in the familiar cannabis high.
Depending on dose and individual response, THC can affect perception, mood, appetite, memory, coordination, and the perception of time.
On a flower label, however, the largest number may actually be THCA, rather than THC.
THCA is the acidic precursor to THC. Heating cannabis through smoking, vaping, or cooking converts a portion of THCA into THC through decarboxylation.
This is also why total THC calculations commonly account for both the THC already present and the potential THC available from THCA.
THC percentage is useful information, but it should not be treated as a complete measure of flower quality. Aroma, genetics, freshness, cure, terpene profile, and the rest of the cannabinoid profile all tell you things a THC number cannot.
Massachusetts cannabis labels and testing requirements also have their own rules for reporting cannabinoid potency. Understanding how laboratory samples represent a larger production batch helps put those percentages in context.
CBD
CBD, or cannabidiol, is one of the most extensively studied cannabinoids after THC and one of the clearest examples of how cannabis research has moved into mainstream clinical science.
It’s vital to contrast the differences of THC vs CBD. Unlike THC, CBD does not produce the traditional cannabis high. It also interacts with the body very differently. Rather than strongly activating CB1 receptors, CBD influences a much broader group of signaling systems, including serotonin receptors, TRP channels, and the endocannabinoid system itself.
That wide-ranging pharmacology has made CBD an important area of research involving anxiety, stress, sleep, neurological conditions, inflammation, and pain.
The strongest established medical evidence for CBD comes from purified pharmaceutical cannabidiol, which is FDA-approved for certain seizure disorders. But research extends well beyond epilepsy. CBD has been used in trials for conditions like depressive disorders, schizophrenia, and PTSD. Although these are still early studies, they offer promising possibolities for future treatments.
Researchers are also studying CBD for sleep and pain. Results vary depending on dose, condition, formulation, and study design, but the growing number of randomized controlled trials gives CBD a much larger human evidence base than most minor cannabinoids.
For recreational consumers, CBD is especially interesting because it can be paired with THC in deliberate ratios. A 1:1 THC product offers a very different cannabinoid profile from THC alone, and changing that cannabinoid ratio can significantly change the balance of a formulation.
THCV
THCV, or tetrahydrocannabivarin, is structurally related to THC but has a distinctly different pharmacological profile.
One of the most interesting differences is the way THCV interacts with cannabinoid receptors. At certain concentrations, THCV can act as a CB1 antagonist while also showing activity at CB2 receptors. Its behavior can change with dose and experimental conditions, giving THCV a cannabinoid profile that is notably different from traditional delta-9 THC.
That unique activity has made THCV especially interesting in research involving appetite, metabolism, glucose regulation, insulin sensitivity, and energy balance.
Preclinical studies have repeatedly produced encouraging findings in these areas, including reduced food intake, improved glucose regulation, increased energy expenditure, and changes in fat metabolism. A 2025 review concluded that THCV shows significant promise for metabolic research, particularly around obesity and diabetes.
There are human findings as well.
Previous clinical research in people with type 2 diabetes found improvements in fasting glucose with THCV, and a more recent placebo-controlled study followed 44 adults taking THCV and CBD formulations for 90 days while examining weight and metabolic outcomes. These studies are helping move the conversation around THCV beyond purely animal or laboratory research.
This research is part of why THCV has developed a reputation as a more energizing, appetite-oriented, or metabolism-focused cannabinoid compared with traditional THC.
The popular nickname "diet weed" oversimplifies the science, but the underlying interest in THCV's relationship with appetite and metabolism did not come out of nowhere. It is rooted in a real and expanding body of cannabinoid research.
Larger human studies will help establish how consistently those findings translate across doses and products, but THCV is already one of the more distinctive minor cannabinoids being studied today.
[ORIGINAL RESEARCH LINK: THCV metabolic, appetite, and human clinical research]
[LINK → /thcv-guide: Explore THCV and the research behind its unique effects]
CBN
CBN, or cannabinol, has become one of the most recognizable cannabinoids in nighttime cannabis products.
Its chemistry also sets it apart from many other minor cannabinoids.
THC can gradually oxidize and break down into CBN as cannabis ages, which is why older flower may contain more CBN than freshly harvested cannabis.
CBN interacts with cannabinoid receptors, but its pharmacology and psychoactivity are substantially different from delta-9 THC. It is generally discussed as much less intoxicating, while still showing biologically active effects that have made it especially interesting to sleep researchers.
Its reputation as a "sleep cannabinoid" is increasingly being tested in controlled human studies.
A 2024 randomized, double-blind, placebo-controlled study involving more than 1,000 participants evaluated several doses of CBN for sleep. That study represents a significant step beyond the earlier era when most discussion of CBN and sleep came from anecdotal reports and preclinical research.
More recently, a 2026 randomized controlled crossover study examined CBN in adults with diagnosed insomnia. While CBN did not significantly improve every measured sleep outcome, the 300mg dose improved several secondary measures, including subjective sleep quality and sleep-onset latency, while also increasing stage N2 sleep and reducing EEG arousals.
Those findings make CBN considerably more interesting than simply saying it is "marketed for sleep."
There is now direct human evidence showing that CBN can influence specific aspects of sleep, even though researchers are still determining the most effective dose, formulation, and combination of cannabinoids.
That research also helps explain why CBN is frequently paired with THC in nighttime gummies, tinctures, and other products. THC and CBN have different pharmacology, so a THC product is designed around a different cannabinoid profile than THC alone. You may notice it paired with other cannabinoids as well as THC, so make sure to be aware of the differences and similarities between CBN vs CBG and other cannabinoid mixtures.
CBG
CBG, or cannabigerol, is one of the most promising minor cannabinoids moving from preclinical research into human studies.
You may hear CBG called the "mother cannabinoid." More precisely, that role belongs to CBGA, cannabigerolic acid.
CBGA is an important biosynthetic starting point in the cannabis plant. Enzymes can convert it into other cannabinoid acids including THCA, CBDA, and CBCA. When CBGA itself is decarboxylated, it becomes CBG.
CBG is generally considered non-intoxicating and has a broad pharmacological profile involving cannabinoid receptors as well as several other biological targets.
Early research has explored CBG in relation to stress, anxiety, mood, inflammation, neurological signaling, antimicrobial activity, and digestive health.
Importantly, CBG research is no longer limited entirely to laboratory or animal models.
A 2024 double-blind, placebo-controlled human trial gave healthy adults 20mg of CBG and found significant reductions in self-reported anxiety and stress compared with placebo. The study also found improved verbal memory and no evidence of intoxication or motor impairment.
That was a relatively small trial, but it represents an important step forward because it directly tested some of CBG's most commonly discussed effects in humans rather than relying only on preclinical evidence.
Those findings also help explain why CBG has developed a reputation among consumers as a cannabinoid associated with a more clear-headed, daytime, focused, or balanced experience.
More human research will help determine which effects are most consistent and what doses work best, but CBG now has promising clinical findings supporting several of the qualities that made consumers interested in it in the first place.
CBC
CBC, or cannabichromene, is a naturally occurring minor cannabinoid with a growing body of research behind it.
Like several other cannabinoids, CBC begins in an acidic form. The cannabis plant converts CBGA into CBCA, which can then decarboxylate into CBC.
CBC is considered non-intoxicating and has a particularly interesting receptor profile. Rather than acting strongly at CB1 receptors like THC, research has found that CBC interacts with several transient receptor potential channels, including TRPV1 and TRPA1, and may also influence the body's own endocannabinoid signaling by affecting anandamide activity. That means that CBC can potentially help regulate mood, memory, and pleasure.
Those mechanisms have made CBC an increasingly active area of cannabinoid research.
Recent reviews have highlighted promising findings related to inflammation, pain signaling, neuroprotection, mood-related pathways, antimicrobial activity, and skin health. Much of this work is still preclinical, but the breadth of CBC's activity is one reason researchers increasingly view it as a cannabinoid with meaningful therapeutic potential rather than simply a trace component of cannabis.
Researchers are also interested in how CBC may work alongside other cannabinoids rather than only in isolation, particularly as scientists continue investigating interactions between multiple components of the cannabis plant.
Human clinical research still needs to catch up with the laboratory and animal findings, but current research gives CBC several promising directions worth following.
Cannabinoids vs Terpenes
Cannabinoids and terpenes are both part of cannabis chemistry, but they are different types of compounds.
Cannabinoids include THC, CBD, CBG, CBN, CBC, and THCV.
Terpenes are aromatic compounds responsible for many of the recognizable smells associated with cannabis and thousands of other plants.
Limonene can contribute citrus-like aromas.
Pinene can smell like pine or fresh herbs.
Linalool can contribute floral notes.
Caryophyllene often brings peppery or spicy aromas.
Myrcene can smell earthy, herbal, musky, or hoppy.
This distinction matters when reading a label.
A flower might contain 25% total THC and 2% total terpenes. Those percentages are measuring completely different groups of compounds.
Terpenes are also frequently marketed as predictors of very specific effects. The science is more complicated.
Laboratory research shows that some terpenes can interact with biological targets, and researchers continue to investigate whether particular cannabinoids and terpenes can influence one another's effects. However, the popular idea that every terpene consistently creates a specific mood or experience is much more definite than the current human evidence supports.
The broader concept often called the "entourage effect" remains an active area of research rather than a universal formula for predicting how every strain will feel.
For shoppers, terpene information is especially useful for understanding aroma and flavor, while cannabinoid information helps describe the product's cannabinoid composition.
Using both gives you a more complete picture than THC percentage alone.
[LINK → /cannabis-terpene-guide: Explore our cannabis terpene guide]
How to Read Cannabinoid Ratios and Labels
Cannabis products increasingly combine cannabinoids in specific ratios.
You might see:
1:1 THC
2:1 CBD
5:1 CBD
1:1 THC
3:1 CBG
The first thing to understand is that a ratio only makes sense when you know which cannabinoid comes first.
A 5:1 CBD product and a 5:1 THC product are very different.
The second thing to understand is that the ratio does not tell you the dose by itself.
For example:
A gummy containing 5mg THC + 5mg CBD is a 1:1 product.
A gummy containing 10mg THC + 10mg CBD is also a 1:1 product.
A tincture containing 100mg THC + 100mg CBD across the entire bottle can also be 1:1.
All three share the same cannabinoid ratio but contain very different amounts.
So read both the ratio and the milligrams per serving.
For flower, labels work a little differently.
You may see separate percentages for THCA, delta-9 THC, CBDA, CBD, CBGA, CBG, and other cannabinoids. These numbers reflect laboratory measurements from a sample representing the production batch.
Acidic cannabinoids such as THCA and CBDA also need to be distinguished from their neutral forms, THC and CBD.
For THC, a commonly used conversion accounts for the mass lost during decarboxylation:
Potential total THC ≈ THC + (THCA × 0.877)
That does not mean every milligram of THCA will convert perfectly when cannabis is consumed. It is a standardized way to estimate THC potential based on molecular weight.
Massachusetts regulates cannabis labeling and laboratory testing, including how cannabinoid information is measured and reported.
If you want a deeper explanation of why a laboratory number represents a batch rather than every individual bud, our Massachusetts testing breakdown covers representative sampling, potency testing, and what a passing result actually means.
[LINK → /blog/massachusetts-cannabis-testing-standards-guide: how Massachusetts cannabis testing and potency labels work]
Cannabinoid ratios are especially common in oils and tinctures, where the format makes it possible to formulate specific combinations and concentrations.
[LINK → /tincture: cannabis tinctures]
Explore Our Individual Cannabinoid Guides
Each cannabinoid functions uniquely, and the distinctions can become confusing for many as there are overlapping attributes. For the best education on the most common cannabinoids, you can visit each of these pages. Our THC guide discusses the basics of how cannabis interacts with our brain. If you are seeking body comfort an relaxation, the CBD guide is a great place to discover more. Those seeking sleep support could benefit from the early scientific findings in our CBN guide. For those seeking relief from stress, the CBG guide reveals new scientific findings. The THCV guide can illuminate how cannabis can potentially aid energy and appetite. And for those seeking education about potential skin and brain health discoveries, the CBC guide is full of new information.
Cannabinoids are only one part of the plant. Aroma, flavor, terpenes, cultivation, product format, freshness, and dose can all matter too.
Cannabinoid FAQs
What are the main cannabinoids in cannabis?
THC and CBD are the two most widely recognized cannabinoids, but cannabis can contain many others, including CBG, CBN, CBC, and THCV. Researchers have identified well over 100 phytocannabinoids, although many appear only in very small amounts.
What is the difference between THC and CBD?
THC is intoxicating and directly activates cannabinoid receptors, particularly CB1 receptors involved in the cannabis high. CBD does not produce the traditional THC-like high and has a substantially different pharmacological profile involving numerous biological targets.
Are CBG, CBN, CBC, and THCV as well studied as THC and CBD?
No. THC and CBD have considerably larger bodies of human research. Research involving CBG, CBN, CBC, and THCV is growing, but many proposed effects are still supported primarily by laboratory, animal, receptor, or small human studies. Product marketing should not be confused with established clinical evidence.
What does a 1:1 cannabinoid ratio mean?
A 1:1 ratio means equal amounts of the two cannabinoids named on the label. For example, a gummy containing 5mg THC and 5mg CBD has a 1:1 THC ratio. Always check the actual milligrams as well because two products can have the same ratio while containing very different doses.
Is CBN proven to make you sleepy?
CBN is widely marketed in nighttime cannabis products, but the scientific evidence is more limited than the marketing can make it appear. CBN may be combined with THC, CBD, and other ingredients in sleep-oriented products, making it difficult to attribute a particular experience to CBN alone. More controlled human research is needed.
Is CBG the mother of all cannabinoids?
That phrase is slightly misleading. CBGA, the acidic precursor to CBG, is an important starting compound that cannabis can convert into other cannabinoid acids, including THCA, CBDA, and CBCA. CBG itself is produced when CBGA is decarboxylated.
Are cannabinoids the same thing as terpenes?
No. Cannabinoids such as THC, CBD, and CBG are one family of cannabis compounds. Terpenes are aromatic compounds responsible for many of cannabis's smells and flavors. Both can contribute information about a product, but they are chemically different.
Does a higher cannabinoid percentage mean better cannabis?
Not necessarily.
Cannabinoid percentages describe part of a product's chemical composition. They do not directly measure cultivation quality, freshness, curing, aroma, trichome preservation, or how enjoyable a particular cultivar will be for an individual consumer.
THC percentage can be useful information without being a quality score.